Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

820898

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with cystic fibrosis who would be eligible for treatment with the drug Orkambi if it were available on the NHS.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122316
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>The number of patients aged 12 and over with cystic fibrosis homozygous for the F508del mutation, in the National Institute for Health and Care Excellence’s (NICE) guidance, that might be eligible for treatment with Orkambi (lumacaftor-ivacaftor) under its marketing authorisation was estimated to be approximately 4,000 during the topic selection considerations that led to the referral of Orkambi to NICE.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 11:37:15 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820918

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential savings accruing to the public purse from reduced hospital admissions in the event that Orkambi were to be made available on the NHS.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122336
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>The Department has made no estimate. Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of resources. In developing its guidance, NICE takes into account all the costs and savings associated with the treatment.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 11:31:59 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820940

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Republic of Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with his Irish counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122358
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>The Government corresponded with the Government of the Republic of Ireland in early 2017 in relation to the cost-effectiveness of Orkambi for the treatment of cystic fibrosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 14:19:09 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820944

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Germany
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has discussed with his German counterpart the cost-effectiveness of Orkambi in that country's health service treatment of cystic fibrosis.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122362
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122370 122372 122374 question first answered 19/01/2018 11:36:20 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820952

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Austria
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with his Austrian counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122370
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122362 122372 122374 question first answered 19/01/2018 11:36:20 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820954

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Denmark
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with his Danish counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122372
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122362 122370 122374 question first answered 19/01/2018 11:36:20 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

820956

registered interest
date	11/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: France
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health of Social Care, whether he has had recent discussions with his French counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	122374
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122362 122370 122372 question first answered 19/01/2018 11:36:20 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

810124

registered interest
date	20/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Accountable Care Organisations
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 11 October 2017 to Question 105277, what the timetable is for the consultation on the new Accountable Care Organisation contract.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	120590
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>NHS England will consult on the draft Accountable Care Organisation contract before any decision is made to issue it as a contract for wider use in the National Health Service.</p><p> </p><p>NHS England has already undertaken wide engagement on this contract, including specific engagement on an early version in December 2016. Responses to the engagement exercise informed further development of an updated version of the draft contract published in August 2017.</p><p> </p><p>It will always be for local commissioners to determine how to best deliver services to meet local needs. It is right that decisions on local services and service models are made by local commissioners, who can best assess how to meet the needs of people in their area. For any significant system reconfiguration, we expect all local parts of the system to be talking to the public and stakeholders regularly — it is vital that people can shape the future of their local services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2018 16:49:02 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden

810125

registered interest
date	20/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Accountable Care Organisations: Private Sector
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether it is his Department's policy that contracts associated with the formation of Accountable Care Organisations will not be outsourced to the private sector.
tabling member constituency	Glasgow East
tabling member printed	David Linden
uin	120591
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>In the very small number of places where local commissioners are running procurements for the award of such contracts, local National Health Service foundation trusts, NHS trusts and general practitioners have been selected as partners for delivery of those contracts.</p><p> </p><p>The selection of an appropriate provider to hold such a contract will continue to be a matter for local NHS commissioners, and those commissioners must make that selection by way of a process which is compliant with the requirements of the Public Contract Regulations 2015. These involve openness, transparency and equal treatment of potential providers.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 121069 question first answered 11/01/2018 16:52:49 answering member 4067 label Biography information for Steve Brine
tabling member	4640 label Biography information for David Linden